Researchers created a new series of modified ipamorelin derivatives using peptidomimetic design, achieving potent GH release with smaller, more drug-like molecules.
Potent GH release retainedSmaller peptidomimetic ipamorelin derivatives maintained strong GH secretagogue activity with improved drug-like properties
What the researchers found
Sequential backbone modifications of ipamorelin produced smaller peptidomimetic compounds that retained potent GH secretagogue activity, advancing the goal of orally active GH-releasing peptides.
Why it matters
Oral bioavailability is a major challenge for peptide therapeutics. This work shows that ipamorelin's core activity can be preserved in smaller, more drug-like molecules, bringing the goal of an oral GH secretagogue closer to reality.
How the study worked
Medicinal chemistry study involving systematic structural modification of ipamorelin, synthesis of peptidomimetic analogs, and in vitro/in vivo GH release assays to evaluate potency.
What this study cannot tell us
Published in 1998 — oral bioavailability data may be preliminary. In vivo pharmacokinetics not fully characterized. Long-term safety of novel peptidomimetics unknown.
How to read the evidence
Medicinal chemistry study published in Journal of Medicinal Chemistry. Strong synthetic and pharmacological work, but clinical translation not demonstrated.
When this study was published
Published in 1998, this represents early peptidomimetic drug design efforts for GH secretagogues. The approach influenced subsequent oral GH secretagogue development.
The bigger picture
Ipamorelin is valued for its selective GH release without significant effects on cortisol or prolactin. Creating oral versions of ipamorelin-like molecules could make GH peptide therapy more accessible and convenient, moving beyond injection-only administration.
Questions still open
- Did any of these ipamorelin derivatives achieve meaningful oral bioavailability?
- Do the modified compounds retain ipamorelin's selectivity for GH over cortisol/prolactin?
- How do these compounds compare to MK-677 in terms of oral activity?
Common questions
Why is making oral peptide drugs so difficult?
How is ipamorelin different from other GH-releasing peptides?
Read the original research
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
Journal of medicinal chemistry, 41(19), 3699-704
Citation
Ankersen, M; Johansen, N L; Madsen, K; Hansen, B S; Raun, K; Nielsen, K K; Thogersen, H; Hansen, T K; Peschke, B; Lau, J; Lundt, B F; Andersen, P H. (1998). A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.. Journal of medicinal chemistry, 41(19), 3699-704.